MHRA launches consultation on new UK rare disease therapies framework to accelerate patient access
Proposed regulatory approach aims to enable earlier patient access and support innovative trial designs
Proposed regulatory approach aims to enable earlier patient access and support innovative trial designs
New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages
2026 Surviving Sepsis Campaign Guidelines and U.S. SEPSIS Act reinforce the need to close persistent therapeutic gaps in septic shock and improve survival through personalized, evidence-based approaches
The U.S. FDA has cleared the Investigational New Drug (IND) application for ABSK061, a highly selective small-molecule FGFR2/3 inhibitor, for the treatment of children with achondroplasia (ACH)
IDE approval by the FDA expands global trial to the United States as first study participant is treated in the United Kingdom
Data presented at the AACR 2026 revealed a 44% reduction and growing urban concentration of U.S. phase I NSCLC trial sites between 2020 and 2024
All patients were negative for minimal residual disease, and no patients experienced progression to active multiple myeloma during the median 15.3 months of follow-up
The investigational drug led to objective response and disease control in patients with late-stage disease
Responses were seen in patients who were not treated with prior KRAS G12C inhibitors as well as those whose disease progressed on prior KRAS G12C inhibitors
An updated trial analysis presented at AACR 2026 showed that the investigational KRAS G12D inhibitor zoldonrasib demonstrated clinical activity with a favorable safety profile in previously treated KRAS G12D‑mutant NSCLC patients
Extended immunotherapy showed manageable long‑term safety in adolescents and young adults with alveolar soft part sarcoma, according to phase II data presented at AACR 2026
The AACR will honor leaders from government and the advocacy community with awards for distinguished service in support of cancer research at the AACR Annual Meeting 2026
SPINRAZA is an antisense oligonucleotide therapy that increases production of survival motor neuron (SMN) protein, essential for motor neuron function
Phesi founder, Dr. Gen Li, shares how patient-centric data science and AI are set to transform global healthcare outcomes in cancer
In this SelectScience interview, discover why AI in clinical data management must prioritize transparency, traceability, and reproducibility to earn trust in regulated environments
New frontiers in glioblastoma: Patient-derived organoids on Axion BioSystems’ Maestro Z impedance-based live-cell analysis system offer new insights into CAR T bioactivity and immunotherapy efficacy
With fewer side effects than traditional therapies, this innovative treatment could redefine care for patients facing limited options
Allyx continues to advance clinical research with its oral compound for neurodegenerative diseases
Dr. Erwin Berthier discusses how remote capillary blood microsampling prioritizes patient experiences while maintaining clinical grade sample quality
myeloMATCH precision medicine clinical trial leverages next-day genomic testing to quickly match patients with appropriate trials across North America
Explore trends and innovations in drug development and the vital role organizations like Alturas Analytics play in overcoming bioanalytical challenges
Study aims to improve detection of women at risk of pregnancy complication
Find out why building expertise in multiplex immunofluorescence is critical in a translational clinical research setting
The beta thalassemia test could help couples make informed reproductive choices, ensure appropriate maternal care, and facilitate diagnosis in infants